Aeovian Pharmaceuticals
Aeovian Pharmaceuticals: Innovating treatments for rare and age-related diseases since 2012.
- 13
- Private company
- Berkeley, CA, USUnited States
Aeovian Pharmaceuticals: Innovating treatments for rare and age-related diseases since 2012.
aeovian.comCrawled Oct 15, 2026
Aeovian is a San Francisco based biopharmaceutical company developing novel and highly selective therapeutics modulating mTORC1 pathway.
Aeovian Pharmaceuticals develops novel CD38 inhibitors targeting neurodegeneration, inflammation, fibrosis, and metabolic diseases. The compounds may address conditions like systemic scleroderma, vascular disorders, and Duchenne muscular dystrophy. The company highlights potential therapeutic applications in liver and metabolic diseases.
May 2026bioworld.comNews article
Aeovian Pharma secures $55 million in Series B funding to complete a Phase II proof-of-concept study for its lead epilepsy drug, AV078, targeting tuberous sclerosis complex (TSC)-related refractory epilepsy. The oversubscribed financing supports clinical development of the candidate in patients with severe, treatment-resistant seizures. Aeovian, a California-based biopharmaceutical company, focuses on advancing novel therapies for neurological disorders.
Dec 2025thepharmaletter.comNews article
Aeovian Pharmaceuticals raises **$55 million in Series B funding** to advance its **mTORC1-targeting therapy** for treating **tuberous sclerosis complex (TSC)**. The company also plans to investigate a separate mechanism for potential applications in **obesity treatment**.
Dec 2025Endpoints NewsNews article
Aeovian Pharmaceuticals secures $55 million in funding to develop a first-in-class selective mTORC1 inhibitor targeting epilepsy linked to Tuberous Sclerosis Complex. The company advances its pipeline with this novel therapeutic approach, aiming to address unmet medical needs in rare neurological disorders. The funding supports clinical development and research for the experimental drug.
Dec 2025Yahoo FinanceNews article